Jazz Pharmaceuticals plc (JAZZ) 25th Annual Needham Virtual Healthcare Conference April 15, 2026 11:45 AM EDT
Company Participants
Philip Johnson – Executive VP & CFO
Jack Spinks – Executive Director of Investor Relations
John Bluth
Conference Call Participants
Ami Fadia – Needham & Company, LLC, Research Division
Presentation
Ami Fadia
Needham & Company, LLC, Research Division
Good morning, everyone, again. Thanks for joining us for this next session with Jazz Pharmaceuticals. I’ve got Phil Johnson, who’s the CFO of the company, along with John Bluth and Jack Spinks from the IR team.
Phil, thank you so much for taking the time to be with us today. What I’d like to do is maybe turn it over to you for some opening remarks, and then we can dive into a Q&A.
Philip Johnson
Executive VP & CFO
No, definitely appreciate it, Ami. Thank you very much for hosting us today. Looking forward to the opportunity to answer questions that are of interest to you and have already enjoyed some of the interactions we’ve had with investors through virtual conference, looking forward to further sessions later today.
Before I get started, please do note that we’ll be making forward-looking statements today. Those are all subject to risks. Actual results could differ materially from what we’re describing. Please do consult our SEC filings for a more fulsome disclosure of the risk factors affecting our business.
And then if we do refer to guidance today, which I’m sure we will, we’re referring to the guidance that we gave on our fourth quarter 2025 earnings call on February 24. So maybe just starting with a high-level overview of where the company is at. 2025 was an exceptional year for Jazz. It was our 21st consecutive year of top line revenue growth. Strong commercial execution across our diversified portfolio delivered record total revenues
